Division of Hologic Inc.
Latest From Cynosure Inc.
Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Despite being a slow month, megadeals abounded in February, as the medtech M&A market saw a hat-trick of billion-dollar deals. Medtech Insight recorded 12 deals for the month, on par with January's volume but down from 16 in February 2016.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Hologic Inc.
- Senior Management
Michael R Davin, Pres. & CEO
Stephen J Webber, EVP, CFO & Chief Accounting Officer
Douglas J Delaney, Chief Commercial Officer
- Contact Info
Phone: (978) 256-4200
5 Carlisle Rd.
Westford, MA 01886
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.